Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable.

Tamara Codilupi Jakub Szybinski Stefanie Arunasalam Sarah Jungius Andrew C Dunbar Simona Stivala Sime Brkic Camille Albrecht Lenka Vokalova Julie L Yang Katarzyna Buczak Nilabh Ghosh Jakob R Passweg Alicia Rovo Anne Angelillo-Scherrer Dmitry Pankov Stephan Dirnhofer Ross L Levine Richard P Koche Sara C Meyer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

We report on a novel mechanism of AXL-MAPK-driven escape from type II JAK2 inhibition, which is targetable at different nodes. This highlights AXL as mediator of acquired resistance warranting inhibition to enhance sustainability of JAK2 inhibition in MPN.

Keyphrases

tyrosine kinase
signaling pathway
oxidative stress
radiation therapy
pi k akt
sentinel lymph node
cell proliferation
rectal cancer